Ascelia Pharma Balance Sheet Health

Financial Health criteria checks 4/6

Ascelia Pharma has a total shareholder equity of SEK107.6M and total debt of SEK26.2M, which brings its debt-to-equity ratio to 24.4%. Its total assets and total liabilities are SEK161.4M and SEK53.8M respectively.

Key information

24.4%

Debt to equity ratio

SEK 26.22m

Debt

Interest coverage ratio	n/a
Cash	SEK 95.72m
Equity	SEK 107.58m
Total liabilities	SEK 53.83m
Total assets	SEK 161.41m

Recent financial health updates

Recent updates

Health Check: How Prudently Does Ascelia Pharma (STO:ACE) Use Debt?

Nov 09

Is Ascelia Pharma (STO:ACE) Using Debt In A Risky Way?

May 31

Is Ascelia Pharma (STO:ACE) In A Good Position To Invest In Growth?

May 11

Ascelia Pharma (STO:ACE) Is In A Good Position To Deliver On Growth Plans

Aug 05

We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth

Jan 24

We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth

Aug 23

Companies Like Ascelia Pharma (STO:ACE) Are In A Position To Invest In Growth

May 19

Here's What Ascelia Pharma AB (publ)'s (STO:ACE) Shareholder Ownership Structure Looks Like

Mar 07

Helena Wennerström Is The Independent Director of Ascelia Pharma AB (publ) (STO:ACE) And They Just Picked Up 125% More Shares

Dec 09

We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth

Nov 26

Financial Position Analysis

Short Term Liabilities: ACE's short term assets (SEK104.0M) exceed its short term liabilities (SEK27.6M).

Long Term Liabilities: ACE's short term assets (SEK104.0M) exceed its long term liabilities (SEK26.2M).

Debt to Equity History and Analysis

Debt Level: ACE has more cash than its total debt.

Reducing Debt: ACE's debt to equity ratio has increased from 0% to 24.4% over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ACE has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if ACE has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.

Discover healthy companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/22 06:47
End of Day Share Price	2024/12/20 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ascelia Pharma AB (publ) is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Lars Hevreng	Danske Bank
Ludvig Svensson	Penser Access
Johan Unnerus	Redeye

Ascelia Pharma Balance Sheet Health

Financial Health criteria checks 4/6

Key information

Recent financial health updates

Health Check: How Prudently Does Ascelia Pharma (STO:ACE) Use Debt?

Is Ascelia Pharma (STO:ACE) Using Debt In A Risky Way?

Is Ascelia Pharma (STO:ACE) In A Good Position To Invest In Growth?

Ascelia Pharma (STO:ACE) Is In A Good Position To Deliver On Growth Plans

We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth

We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth

Recent updates

Ascelia Pharma AB (publ) to Report First Half, 2025 Results on Aug 21, 2025

Key Executive recently bought kr55k worth of stock

Health Check: How Prudently Does Ascelia Pharma (STO:ACE) Use Debt?

Ascelia Pharma AB (Publ) Announces Appointment of Marianne Kock as New Board Member

Ascelia Pharma AB (Publ) Presents Late-Breaking Abstract on Sparkle Data At the American Society of Nephrology Kidney Week Congress 2024

New major risk - Shareholder dilution

Ascelia Pharma AB (publ), Annual General Meeting, Apr 10, 2025

New major risk - Market cap size

Is Ascelia Pharma (STO:ACE) Using Debt In A Risky Way?

VP of Pharmaceutical Development recently bought kr103k worth of stock

New major risk - Revenue and earnings growth

Price target increased by 22% to kr9.75

New major risk - Revenue and earnings growth

Ascelia Pharma AB (publ) Successfully Meets Primary Endpoint with Strong Headline Results in Orvigance Phase 3 Study

Key Executive recently bought kr62k worth of stock

Price target decreased by 61% to kr8.00

New major risk - Revenue and earnings growth

Deputy CEO & Chief Commercial Officer recently bought kr170k worth of stock

Price target decreased by 7.1% to kr19.50

Ascelia Pharma AB (publ) to Report Fiscal Year 2024 Results on Feb 07, 2025

Ascelia Pharma AB (publ) Announces Re-Evaluation Required After Intra-Reader Inconsistency in Scoring of Images from Phase 3 Study SPARKLE

New major risk - Share price stability

Chief Scientific Officer recently bought kr86k worth of stock

New major risk - Revenue and earnings growth

Insufficient new directors

Is Ascelia Pharma (STO:ACE) In A Good Position To Invest In Growth?

Independent Director recently bought kr352k worth of stock

Ascelia Pharma AB (publ) Announces 71 Patients Have Completed the SPARKLE Study

Ascelia Pharma AB (Publ) Announces 65 Patients Completes the Sparkle Study

Price target decreased to kr48.00

Key Executive recently bought kr225k worth of stock

Ascelia Pharma AB (Publ) Announces New Data Show That the Pivotal Phase 3 Clinical Sparkle Study

Price target decreased to kr59.00

Ascelia Pharma AB Announces That the Nomination Committee in Preparation for the Annual General Meeting on 4 May 2023 Has Been Appointed

Ascelia Pharma Presents Results of Orviglance Food Effect Study At RSNA 2022 Showing Strong Liver Enhancement Both with Light Meal and in Fasting Condition

Ascelia Pharma AB (publ) to Report First Half, 2023 Results on Aug 18, 2023

Ascelia Pharma AB (Publ) Announces Resignation of Carl Bjartmar as CMO

Ascelia Pharma AB (publ) Announces Successful Final Results from Orviglance Hepatic Impairment Study

Ascelia Pharma (STO:ACE) Is In A Good Position To Deliver On Growth Plans

Ascelia Pharma AB (publ) Announces Change of CFO

Chief Commercial Officer recently bought kr310k worth of stock

Key Executive recently bought kr101k worth of stock

Chief Executive Officer recently bought kr459k worth of stock

Ascelia Pharma's Food Effect Study Shows Orviglance Image Enhancement of the Liver Is Not Reduced by Light Meal

Price target increased to kr64.00

Insufficient new directors

Ascelia Pharma Suspends Clinical Activities in Russia

Key Executive recently bought kr116k worth of stock

We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth

Ascelia Pharma AB (publ) Receives FDA Acceptance of IND Application for Oncoral Clinical Trial

Ascelia Pharma AB (publ) Announces Results from Orviglance comparison study to gadolinium presented at RSNA 2021

Chief Commercial Officer recently bought kr208k worth of stock

Chief Medical Officer recently bought kr260k worth of stock

We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth

Ascelia Pharma AB (publ) Announces Abstract for Orviglance Comparison Study to Gadolinium Accepted At the Radiology Conference RSNA

Ascelia Pharma AB (publ) Receives Conditional U.S. Food and Drug Administration Acceptance for Orviglance

Chief Executive Officer recently bought kr379k worth of stock

Companies Like Ascelia Pharma (STO:ACE) Are In A Position To Invest In Growth

Chief Executive Officer recently sold kr5.8m worth of stock

Chief Executive Officer exercised options to buy kr11m worth of stock.

Here's What Ascelia Pharma AB (publ)'s (STO:ACE) Shareholder Ownership Structure Looks Like

Chief Medical Officer recently bought kr392k worth of stock

Ascelia Pharma AB (publ) Presents Clinical Development Plan for Oncoral as a Novel Chemotherapy

Ascelia Pharma Gets US Patent for Second Generation Mangoral

Helena Wennerström Is The Independent Director of Ascelia Pharma AB (publ) (STO:ACE) And They Just Picked Up 125% More Shares

Independent Director recently bought kr469k worth of stock

Ascelia Pharma AB (Publ) Announces New Study Shows Mangoral's Lesion Visualization as Effective as Gadolinium Contrast Agent

New 90-day high: kr47.55

We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth